Is visceral obesity the cause of the metabolic syndrome?

References

• Reaven G. M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607
   PubMed Web of Science ®Google Scholar
• Alexander C. M., Landsman P. B., Teutsch S. M., Haffner S. M. NCEP‐defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210–4
   PubMed Web of Science ®Google Scholar
• DeFronzo R. A. Lilly lecture 1987. The triumvirate: beta‐cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667–87
   PubMed Web of Science ®Google Scholar
• Björntorp P. Abdominal obesity and the development of non‐insulin dependent diabetes mellitus. Diabetes Metab Rev 1988; 4: 615–22
   PubMed Web of Science ®Google Scholar
• Kissebah A. H., Peiris A. N. Biology of regional body fat distribution: Relationship to non‐insulin‐dependent diabetes mellitus. Diabetes Metab Rev 1989; 5: 83–109
   PubMed Web of Science ®Google Scholar
• Bajaj M., Defronzo R. A. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 2003; 10: 311–23
   PubMed Web of Science ®Google Scholar
• Lamarche B., Tchernof A., Mauriège P., Cantin B., Dagenais G. R., Lupien P. J., et al. Fasting insulin and apolipoprotein B levels and low‐density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955–61
   PubMed Web of Science ®Google Scholar
• DeFronzo R. A., Ferrannini E. Insulin resistance: A multifaced syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–94
   PubMed Web of Science ®Google Scholar
• Reaven G. M. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473–86
   PubMed Web of Science ®Google Scholar
• Grundy S. M., Brewer H. B., Jr, Cleeman J. I., Smith S. C., Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–8
   PubMed Web of Science ®Google Scholar
• Kissebah A. H., Freedman D. S., Peiris A. N. Health risk of obesity. Med Clin North Am 1989; 73: 111–38
   PubMed Web of Science ®Google Scholar
• Bray G. A. Complications of obesity. Ann Intern Med 1985; 103: 1052–62
   PubMed Web of Science ®Google Scholar
• Pascot A., Lemieux I., Prud'homme D., Tremblay A., Nadeau A., Couillard C., et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001; 42: 2007–14
   PubMed Web of Science ®Google Scholar
• Pouliot M. C., Després J. P., Nadeau A., Moorjani S., Prud'homme D., Lupien P. J., et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41: 826–34
   PubMed Web of Science ®Google Scholar
• Tchernof A., Lamarche B., Prud'homme D., Nadeau A., Moorjani S., Labrie F., et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996; 19: 629–37
   PubMed Web of Science ®Google Scholar
• Lemieux I., Pascot A., Prud'homme D., Alméras N., Bogaty P., Nadeau A., et al. Elevated C‐reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21: 961–7
   PubMed Web of Science ®Google Scholar
• Couillard C., Bergeron N., Prud'homme D., Bergeron J., Tremblay A., Bouchard C., et al. Postprandial triglyceride response in visceral obesity in men. Diabetes 1998; 47: 953–60
   PubMed Web of Science ®Google Scholar
• Després J. P., Moorjani S., Lupien P. J., Tremblay A., Nadeau A., Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497–511
   PubMedGoogle Scholar
• Garg A. Regional adiposity and insulin resistance. J Clin Endocrinol Metab 2004; 89: 4206–10
   PubMed Web of Science ®Google Scholar
• Abate N., Garg A., Peshock R. M., Stray Gundersen J., Adams Huet B., Grundy S. M. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 1996; 45: 1684–93
   PubMed Web of Science ®Google Scholar
• Goodpaster B. H., Thaete F. L., Simoneau J. A., Kelley D. E. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46: 1579–85
   PubMed Web of Science ®Google Scholar
• Tai E. S., Lau T. N., Ho S. C., Fok A. C., Tan C. E. Body fat distribution and cardiovascular risk in normal weight women. Associations with insulin resistance, lipids and plasma leptin. Int J Obes Relat Metab Disord 2000; 24: 751–7
   Web of Science ®Google Scholar
• Nielsen S., Guo Z., Johnson C. M., Hensrud D. D., Jensen M. D. Splanchnic lipolysis in human obesity. J Clin Invest 2004; 113: 1582–8
   PubMed Web of Science ®Google Scholar
• Ross R., Freeman J., Hudson R., Janssen I. Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002; 87: 5044–51
   PubMed Web of Science ®Google Scholar
• Bacha F., Saad R., Gungor N., Janosky J., Arslanian S. A. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab 2003; 88: 2534–40
   PubMed Web of Science ®Google Scholar
• Després J. P., Moorjani S., Ferland M., Tremblay A., Lupien P. J., Nadeau A., et al. Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra‐abdominal fat. Arteriosclerosis 1989; 9: 203–10
   PubMedGoogle Scholar
• Wolf A. M., Beisiegel U., Kortner B., Kuhlmann H. W. Does gastric restriction surgery reduce the risks of metabolic diseases?. Obes Surg 1998; 8: 9–13
   Google Scholar
• Dixon J. B., O'Brien P. A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m(2). Int J Obes Relat Metab Disord 2001; 25: 793–7
   Google Scholar
• Adami G. F., Ravera G., Marinari G. M., Camerini G., Scopinaro N. Metabolic syndrome in severely obese patients. Obes Surg 2001; 11: 543–5
   Google Scholar
• Després J. P., Nadeau A., Tremblay A., Ferland M., Moorjani S., Lupien P. J., et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989; 38: 304–9
   PubMed Web of Science ®Google Scholar
• Marette A., Mauriège P., Marcotte B., Atgié C., Bouchard C., Thériault G., et al. Regional variation in adipose tissue insulin action and GLUT4 glucose transporter expression in severely obese premenopausal women. Diabetologia 1997; 40: 590–8
   PubMedGoogle Scholar
• Zierath J. R., Livingston J. N., Thorne A., Bolinder J., Reynisdottir S., Lonnqvist F., et al. Regional difference in insulin inhibition of non‐esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate‐1 pathway. Diabetologia 1998; 41: 1343–54
   PubMed Web of Science ®Google Scholar
• Adeli K., Taghibiglou C., Van Iderstine S. C., Lewis G. F. Mechanisms of hepatic very low‐density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med 2001; 11: 170–6
   PubMed Web of Science ®Google Scholar
• Arner P. Free fatty acids–do they play a central role in type 2 diabetes?. Diabetes Obes Metab 2001; 3(Suppl 1)S11–9
   Google Scholar
• Després J. P., Ferland M., Moorjani S., Nadeau A., Tremblay A., Lupien P. J. Role of hepatic‐triglyceride lipase activity in the association between intra‐abdominal fat and plasma HDL cholesterol in obese women. Arteriosclerosis 1989; 9: 485–92
   Google Scholar
• Carr M. C., Hokanson J. E., Zambon A., Deeb S. S., Barrett P. H., Purnell J. Q., et al. The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab 2001; 86: 2831–7
   PubMed Web of Science ®Google Scholar
• Onat A., Avci G. S., Barlan M. M., Uyarel H., Uzunlar B., Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004; 28: 1018–25
   PubMed Web of Science ®Google Scholar
• Després J. P. Health consequences of visceral obesity. Ann Med 2001; 33((8))534–41
   Google Scholar
• Miles J. M., Jensen M. D. Counterpoint: visceral adiposity is not causally related to insulin resistance. Diabetes Care 2005; 28: 2326–8
   Google Scholar
• Frayn K. N. Visceral fat and insulin resistance–causative or correlative?. Br J Nutr 2000; 83(Suppl 1)S71–7
   Google Scholar
• Jensen M. D. Lipolysis: contribution from regional fat. Annu Rev Nutr 1997; 17: 127–39
   PubMed Web of Science ®Google Scholar
• Lemieux I. Energy partitioning in gluteal‐femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk?. Arterioscler Thromb Vasc Biol 2004; 24: 795–7
   Web of Science ®Google Scholar
• Björntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991; 14((12))1132–43
   Google Scholar
• Björntorp P. Do stress reactions cause abdominal obesity and comorbidities?. Obes Rev 2001; 2: 73–86
   PubMedGoogle Scholar
• Rebuffe‐Scrive M., Walsh U. A., McEwen B., Rodin J. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiol Behav 1992; 52: 583–90
   PubMed Web of Science ®Google Scholar
• Colao A., Pivonello R., Spiezia S., Faggiano A., Ferone D., Filippella M., et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84: 2664–72
   PubMed Web of Science ®Google Scholar
• Tchernof A., Poehlman E. T. Effects of the menopause transition on body fatness and body fat distribution. Obes Res 1998; 6: 246–54
   PubMedGoogle Scholar
• Elbers J. M., Asscheman H., Seidell J. C., Gooren L. J. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999; 276((2 Pt 1))E317–25
   PubMed Web of Science ®Google Scholar
• Elbers J. M., Giltay E. J., Teerlink T., Scheffer P. G., Asscheman H., Seidell J. C., et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003; 58: 562–71
   PubMed Web of Science ®Google Scholar
• Flier J. S. The adipocyte: storage depot or node on the energy information superhighway?. Cell 1995; 80: 15–8
   PubMed Web of Science ®Google Scholar
• Juhan‐Vague I., Morange P., Renucci J. F., Alessi M. C. Fibrinogen, obesity and insulin resistance. Blood Coagul Fibrinolysis 1999; 10((Suppl 1))S25–8
   Google Scholar
• Juhan‐Vague I., Alessi M. C. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70: 138–43
   PubMed Web of Science ®Google Scholar
• Juhan‐Vague I., Pyke S. D., Alessi M. C., Jespersen J., Haverkate F., Thompson S. G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057–63
   PubMed Web of Science ®Google Scholar
• Juhan‐Vague I., Alessi M. C., Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non‐ insulin‐dependent diabetes mellitus. Ann Med 1996; 28: 371–80
   PubMed Web of Science ®Google Scholar
• Juhan‐Vague I., Alessi M. C. PAI‐1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656–60
   PubMed Web of Science ®Google Scholar
• Juhan‐Vague I., Alessi M. C. Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue. Thromb Haemost 1999; 82: 832–6
   PubMed Web of Science ®Google Scholar
• Yudkin J. S., Stehouwer C. D., Emeis J. J., Coppack S. W. C‐reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999; 19: 972–8
   PubMed Web of Science ®Google Scholar
• Hak A. E., Stehouwer C. D., Bots M. L., Polderman K. H., Schalkwijk C. G., Westendorp I. C., et al. Associations of C‐reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle‐aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986–91
   PubMed Web of Science ®Google Scholar
• Côté M., Mauriège P., Bergeron J., Alméras N., Tremblay A., Lemieux I., et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005; 90: 1434–9
   PubMed Web of Science ®Google Scholar
• Motoshima H., Wu X., Mahadev K., Goldstein B. J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004; 315: 264–71
   PubMed Web of Science ®Google Scholar
• Ukkola O., Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities?. J Mol Med 2002; 80: 696–702
   PubMed Web of Science ®Google Scholar
• Yamamoto Y., Hirose H., Saito I., Tomita M., Taniyama M., Matsubara K., et al. Correlation of the adipocyte‐derived protein adiponectin with insulin resistance index and serum high‐density lipoprotein‐cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002; 103: 137–42
   PubMed Web of Science ®Google Scholar
• Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose‐specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–9
   PubMed Web of Science ®Google Scholar
• Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85–9
   PubMed Web of Science ®Google Scholar
• Pischon T., Girman C. J., Hotamisligil G. S., Rifai N., Hu F. B., Rimm E. B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730–7
   PubMed Web of Science ®Google Scholar
• Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289–304
   PubMed Web of Science ®Google Scholar
• Yarnell J. W. G., Sweetnam P. M., Marks V., Teale J. D., Bolton C. H. Insulin in ischaemic heart disease: are associations explained by triglyceride concentrations? The Caerphilly prospective study. Br Heart J 1994; 71: 293–6
   Google Scholar
• Després J. P., Lamarche B., Mauriège P., Cantin B., Dagenais G. R., Moorjani S., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952–7
   PubMed Web of Science ®Google Scholar
• Welborn T. A., Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154–60
   PubMedGoogle Scholar
• Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131–41
   PubMedGoogle Scholar
• Eschwège E., Richard J. L., Thibult N., Ducimetière P., Warnet J. M., Claude J. R., et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: The Paris prospective study, ten years later. Horm Metab Res 1985; 15((suppl))41–6
   Google Scholar
• Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G. R., Lupien P. J., et al. Small, dense low‐density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997; 95: 69–75
   PubMed Web of Science ®Google Scholar
• Lamarche B., Moorjani S., Lupien P. J., Cantin B., Bernard P. M., Dagenais G. R., et al. Apolipoprotein A‐I and B levels and the risk of ischemic heart disease during a five‐year follow‐up of men in the Québec cardiovascular study. Circulation 1996; 94: 273–8
   PubMed Web of Science ®Google Scholar
• Lemieux I., Lamarche B., Couillard C., Pascot A., Cantin B., Bergeron J., et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men. The Quebec Cardiovascular Study. Arch Intern Med 2001; 161: 2685–92
   PubMed Web of Science ®Google Scholar
• Pirro M., Bergeron J., Dagenais G. R., Bernard P. M., Cantin B., Després J. P., et al. Age and duration of follow‐up as modulators of the risk for ischemic heart disease associated with high plasma C‐reactive protein levels in men. Arch Intern Med 2001; 161: 2474–80
   PubMedGoogle Scholar
• Lemieux I., Lamarche B., St‐Pierre A., Mauriège P., Dagenais G. R., Després J. P. Evidence from the Québec Cardiovascular Study that the Framingham risk chart may not detect a significant proportion of high risk men with the features of the insulin resistance syndrome. Eur Heart J 2001; 22: 630
   Google Scholar
• Lemieux I., Pascot A., Couillard C., Lamarche B., Tchernof A., Alméras N., et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men?. Circulation 2000; 102: 179–84
   PubMed Web of Science ®Google Scholar
• Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97
   PubMed Web of Science ®Google Scholar
• Balkau B., Charles M. A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442–3
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation, Part 1: Diagnosis and classification of Diabetes Mellitus. World Health Organization, Geneva 1999
   Google Scholar
• Alberti K. G., Zimmet P., Shaw J. The metabolic syndrome ‐ a new worldwide definition. Lancet 2005; 366: 1059–62
   PubMed Web of Science ®Google Scholar
• Einhorn D., Reaven G. M., Cobin R. H., Ford E., Ganda O. P., Handelsman Y., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237–52
   PubMedGoogle Scholar
• Gale E. A. M. The myth of the metabolic syndrome. Diabetologia 2005; 48: 1679–83
   PubMed Web of Science ®Google Scholar
• Tuomilehto J., Lindstrom J., Eriksson J. G., Valle T. T., Hamalainen H., Ilanne‐Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50
   PubMed Web of Science ®Google Scholar
• Knowler W. C., Barrett‐Connor E., Fowler S. E., Hamman R. F., Lachin J. M., Walker E. A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403
   PubMed Web of Science ®Google Scholar
• Torgerson J. S., Hauptman J., Boldrin M. N., Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–61
   PubMed Web of Science ®Google Scholar
• Després J. P. Dyslipidaemia and obesity. Baillieres Clin Endocrinol Metab 1994; 8: 629–60
   PubMed Web of Science ®Google Scholar
• Després J. P., Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev 1993; 6: 137–59
   PubMedGoogle Scholar
• Després J. P. Obesity and lipid metabolism: relevance of body fat distribution. Curr Opin Lipidol 1991; 2: 5–15
   Google Scholar
• Goodpaster B. H., Kelly D. E., Wing R. R., Meier A., Thaete F. L. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999; 48: 839–47
   PubMed Web of Science ®Google Scholar
• Leenen R., van der Kooy K., Deurenberg P., Seidell J. C., Weststrate J. A., Schouten F. J. M., et al. Visceral fat accumulation in obese subjects: relation to energy expenditure and response to weight loss. Am J Physiol 1992; 263: E913–9
   Google Scholar
• Zamboni M., Armellini F., Turcato E., Todesco T., Bissoli L., Bergamo‐Andreis I. A., et al. Effect of weight loss on regional body fat distribution in premenopausal women. Am J Clin Nutr 1993; 58: 29–34
   PubMed Web of Science ®Google Scholar
• van der Kooy K., Leenen R., Seidell J. C., Deurenberg P., Droop A., Bakker C. J. Waist‐hip ratio is a poor predictor of changes in visceral fat. Am J Clin Nutr 1993; 57: 327–33
   PubMed Web of Science ®Google Scholar
• Ross R., Dagnone D., Jones P. J., Smith H., Paddags A., Hudson R., et al. Reduction in obesity and related comorbid conditions after diet‐induced weight loss or exercise‐induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000; 133: 92–103
   PubMed Web of Science ®Google Scholar
• Rice B., Janssen I., Hudson R., Ross R. Effects of aerobic or resistance exercise and/or diet on glucose tolerance and plasma insulin levels in obese men. Diabetes Care 1999; 22: 684–91
   PubMed Web of Science ®Google Scholar
• Després J. P., Lemieux I., Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716–20
   PubMed Web of Science ®Google Scholar